Methandrostenolone: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
Line 34: Line 34:
* [http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=1928923 The Effect of Methandrostenolone on Nitrogen Excretion Following Open-Heart Surgery ]Walter Zingg, Can Med Assoc J, Oct.9, 1965, vol 93
* [http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=1928923 The Effect of Methandrostenolone on Nitrogen Excretion Following Open-Heart Surgery ]Walter Zingg, Can Med Assoc J, Oct.9, 1965, vol 93
<div class="references-small">
<div class="references-small">
<references />
{{reflist|2}}
</div>
</div>



Revision as of 19:33, 4 September 2012


Methandrostenolone
Error creating thumbnail: File missing
Clinical data
Pregnancy
category
  • US: X (Contraindicated)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic
Elimination half-life4.5-6 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H28O2
Molar mass300.441 g/mol

WikiDoc Resources for Methandrostenolone

Articles

Most recent articles on Methandrostenolone

Most cited articles on Methandrostenolone

Review articles on Methandrostenolone

Articles on Methandrostenolone in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Methandrostenolone

Images of Methandrostenolone

Photos of Methandrostenolone

Podcasts & MP3s on Methandrostenolone

Videos on Methandrostenolone

Evidence Based Medicine

Cochrane Collaboration on Methandrostenolone

Bandolier on Methandrostenolone

TRIP on Methandrostenolone

Clinical Trials

Ongoing Trials on Methandrostenolone at Clinical Trials.gov

Trial results on Methandrostenolone

Clinical Trials on Methandrostenolone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Methandrostenolone

NICE Guidance on Methandrostenolone

NHS PRODIGY Guidance

FDA on Methandrostenolone

CDC on Methandrostenolone

Books

Books on Methandrostenolone

News

Methandrostenolone in the news

Be alerted to news on Methandrostenolone

News trends on Methandrostenolone

Commentary

Blogs on Methandrostenolone

Definitions

Definitions of Methandrostenolone

Patient Resources / Community

Patient resources on Methandrostenolone

Discussion groups on Methandrostenolone

Patient Handouts on Methandrostenolone

Directions to Hospitals Treating Methandrostenolone

Risk calculators and risk factors for Methandrostenolone

Healthcare Provider Resources

Symptoms of Methandrostenolone

Causes & Risk Factors for Methandrostenolone

Diagnostic studies for Methandrostenolone

Treatment of Methandrostenolone

Continuing Medical Education (CME)

CME Programs on Methandrostenolone

International

Methandrostenolone en Espanol

Methandrostenolone en Francais

Business

Methandrostenolone in the Marketplace

Patents on Methandrostenolone

Experimental / Informatics

List of terms related to Methandrostenolone

Methandrostenolone (Dianabol) is an anabolic steroid originally developed by John Ziegler and released in the US in 1958 by Ciba.[1][2] It was used as an aid to muscle growth by bodybuilders until its ban by the FDA under the Controlled Substances Act.

Methandrostenolone does not react strongly with the androgen receptor[3], instead relying on activity not mediated by the receptor for its effects. These include dramatic increases in protein synthesis, glycogenolysis, and muscle strength over a short space of time. However, due to its mode of action, it decreases the rate of cell respiration and decreases production of red blood cells. In high doses (30 mg or more per day), side effects such as gynaecomastia, high blood pressure, acne and male pattern baldness may begin to occur. The drug causes severe masculinising effects in women even at low doses. In addition, it is metabolized into estradiol by aromatase. This means that without the administration of aromatase inhibitors such as Anastrozole or Aminoglutethimide, estrogenic effects will appear over time in men. Many users will combat the estrogenic side effects with Nolvadex or Clomid. In addition, as with other 17α-alkylated steroids, the use of methandrostenolone over extended periods of time can result in liver damage without appropriate care.

In the early 1960s, doctors commonly prescribed a tablet per day for women as a tonic. This use was quickly discontinued upon discovery of the heavily masculinising effects of methandrostenolone. However, despite the lack of any known therapeutic applications, the drug remained legal until the early 1990s.

The 17α-methylation of the steroid does allow it to pass through the liver without being broken down (hence causing the aforementioned damage to the liver) allowing it to be taken orally. It also has the effect of decreasing the steroid's affinity for sex hormone binding globulin, a protein that de-activates steroid molecules and prevents them from further reactions with the body. As a result, methandrostenolone is significantly more active than an equivalent quantity of testosterone, resulting in rapid growth of muscle tissue. However, the concomitant elevation in estrogen levels - a result of the aromatization of methandrostenolone - results in significant water retention. This gives the appearance of great gains in mass and strength, which prove to be temporary once the steroid is discontinued and water weight drops. Because of this, it is often used by bodybuilders only at the start of a "steroid cycle", to facilitate rapid strength increases and the appearance of great size, while compounds such as testosterone or nandrolone with long acting esters build up in the body to an appreciable amount capable of supporting anabolic function on their own.

References

  1. NIDA Research Monograph 1990, Number 102, p97 [1]
  2. Journal of Sport History, 1993, Vol.20 p2 [2]
  3. The effect of anabolic-androgenic steroids on aromatase activity and androgen receptor binding in the rat preoptic area. Brain Research 1998 May 11;792(2):271-6.

Template:Anabolic steroids de:Metandienon sv:Dianabol


Template:WikiDoc Sources